Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 12/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127355 | 0.89 | GABRA1 (0.35) | GABRA1HCRTR1HCRTR2IDH1BRD4 | |
| SCHEMBL19686410 | 0.89 | GABRA1 (0.35) | GABRA1HCRTR1HCRTR2IDH1BRD4 | |
| SCHEMBL21165971 | 0.87 | GABRA1 (0.40) | GABRA1ROCK2IDH1NNMT | |
| SCHEMBL31127359 | 0.84 | IDH1 (0.35) | ROCK2IDH1SYKBRD4 | |
| SCHEMBL19687101 | 0.84 | IDH1 (0.35) | ROCK2IDH1SYKBRD4 | |
| SCHEMBL19687062 | 0.84 | IDH1 (0.36) | GABRA1IDH1ENPP2 | |
| SCHEMBL19687146 | 0.83 | IDH1 (0.33) | GABRA1IDH1 | |
| SCHEMBL19687058 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2IDH1BRD4 | |
| SCHEMBL19686407 | 0.81 | IDH1 (0.38) | IDH1 | |
| SCHEMBL19686777 | 0.80 | IDH1 (0.34) | IDH1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | GABRA1 325/4885ROCK2 3705/4885HCRTR1 2875/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | GABRA1 325/4885ROCK2 3705/4885HCRTR1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.